The present invention relates to certain compounds (e.g., imidazo[1,2-a]pyridine, imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds) of the formula: wherein X1 and X2 are C or N X3 and X4 are N or CR2 provided that at least 2 of X1, X2, X3 and X4 are N the dashed line (along with the adjacent solid line) indicates the position of a single or double bond R1 is hydrogen, optionally substituted phenyl or other substituents Ring A is optionally substituted phenyl, 5-6-membered heteroaryl or 5,6-bicyclic heteroaryl R2 is hydrogen, halogen, optionally substituted C1-6alkyl optionally substituted carbocyclyl, -ORA or N(RB)2 RA and RB are hydrogen or substituents that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prevention and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, autoimmune diseases, metabolic diseases, and neurodegenerative diseases (e.g. Alzheimers disease)).
